Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

Autor:	Victoria Kehl, Mark Thalgott, Jürgen E. Gschwend, Margitta Retz, Matthias Heck, Bernd J. Krause, Roman Nawroth, Michael Souvatzoglou, Caroline Kronester, Brigitte Rack, Matthias Eiber, Ulrich Andergassen
Rok vydání:	2015
Předmět:	Oncology Male Cancer Research medicine.medical_specialty Docetaxel Disease-Free Survival Prostate cancer Circulating tumor cell Surgical oncology Internal medicine Genetics Biomarkers Tumor Medicine Humans Neoplasm Metastasis Precision Medicine neoplasms Aged Proportional Hazards Models Aged 80 and over business.industry Surrogate endpoint Proportional hazards model Circulating tumor cells Middle Aged medicine.disease Neoplastic Cells Circulating Prognosis ddc Clinical trial Prostatic Neoplasms Castration-Resistant Treatment Outcome Personalized treatment Treatment efficacy Taxoids Stem cell CTCs business Biomarkers medicine.drug Research Article
Zdroj:	BMC Cancer
Popis:	Background Circulating tumor cell (CTCs) counts might serve as early surrogate marker for treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) patients. We prospectively assessed categorical and continuous CTC-counts for their utility in early prediction of radiographic response, progression-free (PFS) and overall survival (OS) in mCRPC patients treated with docetaxel. Methods CTC-counts were assessed in 122 serial samples, as continuous or categorical (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7a512b6088717aa23fda366707a5d7 https://mediatum.ub.tum.de/doc/1342583/document.pdf Zobrazit plný text záznamu